Onset of inflammatory bowel diseases during combined ??-interferon and ribavirin therapy for chronic hepatitis C: report of two cases

2005 ◽  
Vol 17 (11) ◽  
pp. 1243-1245 ◽  
Author(s):  
Federica Villa ◽  
Maria Grazia Rumi ◽  
Clementina Signorelli ◽  
Simone Saibeni ◽  
Ersilio Del Ninno ◽  
...  
2012 ◽  
Vol 6 (5) ◽  
pp. 626-627 ◽  
Author(s):  
Cumali Efe ◽  
Emir Charles Roach ◽  
Tugrul Purnak ◽  
Ersan Ozaslan

2021 ◽  
Vol 5 (2) ◽  
pp. 111-117
Author(s):  
G. V. Volynets ◽  

The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%. The clinical course of these concurrent diseases, the possibility of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation during immunosuppressive therapy are described. Recommendations on the peculiarities of examination and management of patients with concurrent pathology of IBD and CVH are presented. The combined pathology of IBD and CVH is a significant public health problem worldwide that requires further largescale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should occur on an individual basis.


2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Cumali Karatoprak ◽  
Elif Arabaci ◽  
Kemal Yildiz ◽  
Mustafa Cakirca ◽  
Mehmet Ali Cikrikcioglu ◽  
...  

Rarely, leukocytoclastic vasculitis can result from ischemic colitis, inflammatory bowel disease, and cryoglobulinemia. There is no established standard for the treatment of leukocytoclastic vasculitis associated with gastroenterologic diseases. This paper presents three cases of leukoytoclastic vasculitis, each of which is associated with a different gastroenterologic condition: ischemic colitis, Crohn’s disease, and chronic hepatitis C. Each condition went into remission by treatment of leukocytoclastic vasculitis, regardless of the underlying disease.


2021 ◽  
Vol 53 ◽  
pp. S179
Author(s):  
G. Losurdo ◽  
A. Iannone ◽  
A. Contaldo ◽  
M. Barone ◽  
E. Ierardi ◽  
...  

2021 ◽  
Vol 11 (2) ◽  
pp. 29-34
Author(s):  
G.V. Volynets ◽  
◽  
A.I. Khavkin ◽  

The article presents the results of a literature review devoted to the study of the problems of the combined course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), and chronic viral hepatitis (CVH) – chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The frequency of occurrence of CHB and CHC in IBD in different countries is presented, which ranges from 1 to 9%. The clinical course of these combined diseases, the possibility of reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) during immunosuppressive therapy are described. Recommendations on the specifics of examination and management of patients with combined pathology of IBD and CVH are presented. Conclusion. The combined pathology of IBD and CVH is a significant public health problem around the world that requires further large-scale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should be individualized. Key words: inflammatory bowel disease, chronic hepatitis B, chronic hepatitis C, immunosuppressive therapy


2000 ◽  
Vol 39 (3) ◽  
pp. 212-214 ◽  
Author(s):  
Hiroyuki Banno ◽  
Hiromichi Takama ◽  
Yukiko Nitta ◽  
Toshihiko Ikeya ◽  
Yoshifumi Hirooka

Sign in / Sign up

Export Citation Format

Share Document